Re-Vana Therapeutics
Re-Vana Therapeutics is dedicated to advancing the quality of care for patients suffering from sight-threatening diseases through innovative sustained-release therapeutics. They develop and deliver in-clinic, photocrosslinked, biodegradable ocular biologics and small-molecule drugs with a focus on long-acting delivery systems.
Industries
Nr. of Employees
small (1-50)
Re-Vana Therapeutics
Products
Pre‑formed photocrosslinked biodegradable ocular implant (low-to-moderate release)
A pre‑formed, visible‑light photocrosslinked biodegradable implant engineered for sustained intraocular release up to approximately 6 months with adjustable release rates (example cited: ~0.1–0.625 µg/day) via polymer and crosslinking adjustments.
Pre‑formed high‑rate biodegradable ocular implant (for biologics)
A formulation variant of the pre‑formed implant optimized to deliver higher intraocular release rates (example cited: up to ~2 µg/day) suitable for potent biologics and biosimilars, with release governed by polymer, crosslinking and loading parameters.
Injectable in‑situ forming photo‑crosslinked ocular implant
An injectable gel system that undergoes phase inversion and visible‑light photo‑crosslinking after injection through a narrow‑gauge needle to form an implant in situ, supporting sustained release for 6–12 months and higher release rates (>4 µg/day) as described.
Pre‑formed photocrosslinked biodegradable ocular implant (low-to-moderate release)
A pre‑formed, visible‑light photocrosslinked biodegradable implant engineered for sustained intraocular release up to approximately 6 months with adjustable release rates (example cited: ~0.1–0.625 µg/day) via polymer and crosslinking adjustments.
Pre‑formed high‑rate biodegradable ocular implant (for biologics)
A formulation variant of the pre‑formed implant optimized to deliver higher intraocular release rates (example cited: up to ~2 µg/day) suitable for potent biologics and biosimilars, with release governed by polymer, crosslinking and loading parameters.
Injectable in‑situ forming photo‑crosslinked ocular implant
An injectable gel system that undergoes phase inversion and visible‑light photo‑crosslinking after injection through a narrow‑gauge needle to form an implant in situ, supporting sustained release for 6–12 months and higher release rates (>4 µg/day) as described.
Services
Preformulation and preclinical feasibility studies
Collaborative studies to evaluate formulation approaches and preclinical performance of sustained‑release ocular therapeutics.
Technology partnering and licensing collaborations
Strategic collaborations to apply photocrosslinked sustained‑release delivery platforms to partner assets and to support commercialization pathways.
Formulation development for long‑acting ocular therapeutics
Development of formulation variants for different APIs (biologics and small molecules) to achieve target release rates and durations through polymer and crosslinking modulation.
Preformulation and preclinical feasibility studies
Collaborative studies to evaluate formulation approaches and preclinical performance of sustained‑release ocular therapeutics.
Technology partnering and licensing collaborations
Strategic collaborations to apply photocrosslinked sustained‑release delivery platforms to partner assets and to support commercialization pathways.
Formulation development for long‑acting ocular therapeutics
Development of formulation variants for different APIs (biologics and small molecules) to achieve target release rates and durations through polymer and crosslinking modulation.
Expertise Areas
- Ocular drug delivery
- Extended‑release (long‑acting) therapeutics
- Formulation and preformulation development
- Drug‑device combination development
Key Technologies
- Visible‑light photocrosslinking
- Biodegradable polymer implants
- In‑situ forming injectable gels
- Phase inversion